Pfizer Inc. (PFE) Unit Quigley Pharma Inc. (QGLY) To Exit Ch. 11 With $265M Asbestos Settlement
3/23/2011 6:50:16 AM
More...
|
Quigley Corporation (QGLY) Announces Final Results of Quigley Pharma Inc. (QGLY)'s Phase IIb Study
7/22/2009 8:34:28 AM
More...
|
Dissident Stockholder Ted Karkus Found to Have Undisclosed Financial Arrangements With Dr. Richard A. Rosenbloom, COO Of Quigley Pharma Inc. (QGLY), From 2008 to Date of Proxy: Rosenbloom Suspended Without Pay Pending Further Investigation
5/19/2009 11:28:24 AM
More...
|
Quigley Pharma Inc. (QGLY) Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter
11/12/2008 8:27:23 AM
More...
|
Quigley Pharma Inc. (QGLY) Evaluates Regulatory and Market Opportunities for Anti-Inflammatory / Cytokine Modifying Compound
8/1/2007 11:58:28 AM
More...
|
Quigley Pharma Inc. (QGLY) Begins Human Trial to Investigate Effects of Broad Spectrum Anti-Inflammatory Compound on Metabolic Syndrome Patients
7/30/2007 8:59:29 AM
More...
|
Quigley Pharma Inc. (QGLY) Granted Patent For Prophylactic And Anti-Transmissivity Uses Of An Anti-Microbial Composition
2/12/2007 12:35:33 PM
More...
|
Quigley Pharma Inc. (QGLY) Broad Spectrum Anti-Viral QR-441(a) Shown To Be Effective Against Two Problematic Pathogens To The Poultry Industry
1/8/2007 3:06:44 PM
More...
|
Quigley Pharma Inc. (QGLY)'s QR-333 Phase IIb Clinical Study Has Commenced; Drug Product And Clinical Trial Sites Prepared For Phase IIb Study Of Lead Drug Candidate
11/20/2006 9:51:51 AM
More...
|
Quigley Pharma Inc. (QGLY)'s Radioprotective Compound QR-336 Shown To Be Most Effective In Oral And Subcutaneous Injection Dose Forms in Animal Model Study
10/3/2006 10:59:46 AM
More...
|
|